Search Result

Results for "

KIT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	c-Kit (117) Akt (2) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (43) Aurora Kinase (2) Autophagy (31) Bcr-Abl (17) Biochemical Assay Reagents (1) c-Fms (18) c-Met/HGFR (9) c-Myc (1) Casein Kinase (1) CDK (1) Checkpoint Kinase (Chk) (1) Discoidin Domain Receptor (4) Drug Metabolite (12) Drug-Linker Conjugates for ADC (2) E3 Ligase Ligand-Linker Conjugates (1) EGFR (4) FAK (2) Ferroptosis (5) FGFR (30) FLT3 (33) IKK (1) Isotope-Labeled Compounds (9) JAK (3) NAMPT (1) NO Synthase (2) PDGFR (83) PDK-1 (1) Pim (1) PKA (1) PKC (3) PROTACs (1) RAD51 (2) Raf (15) RET (23) SARS-CoV (5) Small Interfering RNA (siRNA) (3) Src (8) Syk (1) TAM Receptor (5) Tie (5) Trk Receptor (3) VEGFR (70) Wnt (1)
By Research Areas:	Cancer (155) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (13) Neurological Disease (3)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

174

Inhibitors & Agonists

Biochemical Assay Reagents

MCE Kits

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: c-Kit

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15240

*c-Kit-IN-1*	c-Kit c-Met/HGFR	Cancer
c-Kit-IN-1 is a potent inhibitor of *c-Kit* and c-Met with IC₅₀s of <200 nM.

HY-18302

*c-Kit-IN-5-1*	c-Kit	Inflammation/Immunology
c-Kit-IN-5 is potent inhibitor of *c-Kit, with IC₅₀s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit* over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties .

HY-RS07319

KIT Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
KIT Human Pre-designed siRNA Set A contains three designed siRNAs for KIT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

KIT Human Pre-designed siRNA Set A KIT Human Pre-designed siRNA Set A

HY-RS07320

Kit Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Kit Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kit gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kit Mouse Pre-designed siRNA Set A Kit Mouse Pre-designed siRNA Set A

HY-RS07321

Kit Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Kit Rat Pre-designed siRNA Set A contains three designed siRNAs for Kit gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kit Rat Pre-designed siRNA Set A Kit Rat Pre-designed siRNA Set A

HY-168580

*c-Kit-IN-7*	c-Kit	Cancer
c-Kit-IN-7 (Compound 104) is a potent inhibitor of *c-Kit, with IC₅₀* values of ≤10 nM. c-Kit-IN-7 inhibits the cell proliferation in GIST430 and BaF3 mutants, with IC₅₀ values of ≤100 nM. c-Kit-IN-7 plays an important role in cancer driven by c-KIT kinase mutations research .

HY-101034

*CHMFL-ABL/KIT-155* CHMFL-ABL-KIT-155	Bcr-Abl c-Kit Apoptosis PDGFR Discoidin Domain Receptor	Cancer
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC₅₀s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC₅₀=81 nM), CSF1R (IC₅₀=227 nM), DDR1 (IC₅₀=116 nM), DDR2 (IC₅₀=325 nM), LCK (IC₅₀=12 nM) and PDGFRβ (IC₅₀=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis .

HY-128589

*CHMFL-KIT-033*	c-Kit	Cancer
CHMFL-KIT-033 is a potent and selective inhibitor of *c-KIT* T670I mutant for gastrointestinal stromal tumors (GISTs), with an IC₅₀** of 0.045 μM .

HY-168579

*c-Kit-IN-6*	c-Kit	Cancer
c-Kit-IN-6 (Compound 101) is an inhibitor of *c-Kit* with an IC₅₀ value ranging between 100 nM and 1 μM. Additionally, c-Kit-IN-6 can inhibit the proliferation of GIST430 and BaF3 mutant cells .

HY-168581

*c-Kit-IN-8*	c-Kit	Cancer
c-Kit-IN-8 (Compound 53) is an inhibitor for *c-Kit* kinase, that inhibits uKIT kinase with an IC₅₀** > 1 μM. c-Kit-IN-8 inhibits the proliferation of cancer cell GIST430 and BaF3 wildtype and mutants with IC₅₀ > 0.1 μM .

HY-128602

*c-Kit-IN-2*	c-Kit	Cancer
c-Kit-IN-2 is a *c-KIT* inhibitor with an IC₅₀ of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI₅₀s of 3, 1, and 2 nM, respectively .

HY-KT001

E3 Ligase Ligand-Linker Conjugate Kit	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-Linker Conjugate Kit is a series of synthesized compounds that incorporate an E3 ligase ligand and a linker used in PROTAC technology.

HY-132451S

(R,S)-4-Hydroxy Cyclophosphamide-d4 Preparation Kit	Isotope-Labeled Compounds	Cancer
(R,S)-4-Hydroxy Cyclophosphamide-d₄ Preparation Kit is the deuterium labeled (R,S)-4-Hydroxy Cyclophosphamide Preparation Kit. (R,S)-4-Hydroxy Cyclophosphamide is an isomer of 4-Hydroxycyclophosphamide, the active metabolite of the cytotoxic alkylating agent Cyclophosphamide (HY-17420) .

HY-P99462

Barzolvolimab CDX 0159	c-Kit	Inflammation/Immunology
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .

HY-145557

Bezuclastinib CGT9486; PLX 9486	c-Kit	Cancer
Bezuclastinib (CGT9486) is an orally active, highly selective tyrosine kinase inhibitor with potent activity against KIT D816V. Bezuclastinib can be used for the research of nonadvanced systemic mastocytosis (NonAdvSM) .

HY-18317

JNJ-38158471	VEGFR RET c-Kit	Cancer
JNJ-38158471 is a well tolerated, orally available, highly selective VEGFR-2 inhibitor, with an IC₅₀ of 40 nM. JNJ-38158471 also inhibits Ret and *Kit* with IC₅₀s of 180 and 500 nM, respectively .

HY-P990002

*Anti-Mouse CD117/c-Kit* Antibody (2B8)**	c-Kit	Cancer
Anti-Mouse CD117/c-Kit Antibody (2B8) is an IgG2b antibody inhibitor against mouse CD117. Derived from rat.

HY-W143698

PDGFRα kinase inhibitor 2	Bcr-Abl c-Kit PDGFR	Cancer
PDGFRα kinase inhibitor 2 (compound 1), an Imatinib (HY-15463) analogue, is a covalent and irreversible kinase inhibitor with IC₅₀s of 6.95 μM, 2.45 μM, 1.39 μM for ABL1 wt, *KIT* wt, PDGFRR wt .

HY-15198

KG5	Raf PDGFR FLT3 c-Kit	Cancer
KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3, *KIT* and c-Raf. KG5 has anticancer, antiangiogenic activities .

HY-139996

Pomalidomide-C5-Dovitinib	PROTACs Apoptosis FLT3 c-Kit FGFR VEGFR PDGFR c-Fms	Cancer
Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC containing Pomalidomide, Dovitinib and connected with CRBN. Pomalidomide-C5-Dovitinib shows enhanced antiproliferative effects against FLT3-ITD+ AML cells. Pomalidomide-C5-Dovitinib induces the degradation of the FLT3-ITD and KIT proteins in a ubiquitin-proteasome-dependent manner and completely blocks their downstream signaling pathway. Pomalidomide-C5-Dovitinib has the potential for the research of FLT3-ITD ⁺ acute myeloid leukemia .

HY-121708

KI-328	Others	Cancer
KI-328 is a novel inhibitor targeting KIT kinase that has selective activity against some KIT mutant kinases commonly found in acute myeloid leukemia (AML). KI-328 showed specificity for KIT kinase in in vitro kinase assays and inhibited the growth of wild-type (Wt) and mutant KIT-expressing cells, but had lower activity against D816V-KIT. Comparative analysis of the inhibitory effects of several potent KIT inhibitors on the growth of multiple mutant KIT-expressing cells showed that the multi-kinase inhibitors had comparable activity against D816V-KIT as against other mutant KITs; however, heat shock protein 90 (HSP90) inhibitors showed significant activity against D816V-KIT, inhibiting the growth of D816V-KIT-expressing cells at concentrations that did not affect the growth of other mutant KIT-expressing cells. These results suggest that potent KIT inhibitors have different activities against different types of KIT mutant kinases. Therefore, in clinical development, KIT inhibitors need to validate their activity against multiple types of KIT mutant kinases.

HY-132166

M4205	c-Kit	Cancer
M4205 is a *c-KIT* inhibitor, with an IC₅₀ of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17.

HY-10638

AP23464	c-Kit Apoptosis	Cancer
AP23464 is an ATP-based inhibitor for *Kit, that inhibits the phosphorylation of Kit* wildtype and mutants, with IC₅₀ of 5-85 nM. AP23464 inhibits the proliferation of Kit mutated cells (IC₅₀ is 3-20 nM), arrests the cell cycle at G0/G1 phase, and induces apoptosis in Kit mutated cells .

HY-16961

Sitravatinib 3 Publications Verification MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-16961A

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-112802

AZD3229	c-Kit	Cancer
AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. AZD3229 inhibits c-KIT with an IC₅₀ value of 223.3 nM .

HY-10331S

Regorafenib-d3 BAY 73-4506-d₃	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib-d₃ is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].

HY-101443

ISCK03 3 Publications Verification	c-Kit	Inflammation/Immunology
ISCK03 is a *SCF/c-Kit* and CD117-specific inhibitor. ISCK03 significantly inhibits c-Kit phosphorylation at 10 μM .

HY-156619

Labuxtinib	c-Kit	Cancer
Labuxtinib is c-kit tyrosine kinase inhibitor .

HY-10873

N-Desethyl Sunitinib 5 Publications Verification SU-12662	Drug Metabolite	Cancer
N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and *KIT* inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

HY-138813

N-Desethyl Sunitinib hydrochloride 5 Publications Verification SU-12662 hydrochloride	Drug Metabolite	Cancer
N-Desethyl Sunitinib (SU-12662) (hydrochloride) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and *KIT* inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

HY-112452

SU11652	VEGFR FGFR PDGFR c-Kit Apoptosis	Cancer
SU11652 is a potent receptor tyrosine kinase (RTK) inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, FGFR, PDGFR, and *Kit. SU11652 can be uesd for spontaneous cancers expressing Kit* mutations research .

HY-112802A

AZD3229 Tosylate	c-Kit	Cancer
AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

HY-P990020

Eglatoprutug	Others c-Kit	Others
Eglatoprutug is an humanized immunoglobulin G1-kappa, anti-c-Kit monoclonal antibody .

HY-13838

PLX647	c-Fms c-Kit	Cancer
PLX647 is an orally active, highly specific dual FMS and *KIT* kinase inhibitor, with IC₅₀s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC₅₀s=91 and 130 nM, respectively) .

HY-10873S

N-Desethyl Sunitinib-d5	Isotope-Labeled Compounds Drug Metabolite	Cancer
N-Desethyl Sunitinib-d₅ is the deuterium labeled N-Desethyl Sunitinib. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively[1].

HY-13838A

PLX647 dihydrochloride	c-Fms c-Kit	Inflammation/Immunology Cancer
PLX647 dihydrochloride is an orally active, highly specific dual FMS and *KIT* kinase inhibitor, with IC₅₀s of 28 and 16 nM, reapectively. PLX647 dihydrochloride shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC₅₀s=91 and 130 nM, respectively) .

HY-10873S2

N-Desethyl Sunitinib-d5 hydrochloride SU-12662-d₅ hydrochloride	Isotope-Labeled Compounds Drug Metabolite	Cancer
N-Desethyl Sunitinib-d5 (hydrochloride) is a deuterated labeled N-Desethyl Sunitinib . N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and *KIT* inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

HY-50946

Imatinib Mesylate 80+ Cited Publications STI571 Mesylate; CGP-57148B Mesylate	c-Kit Bcr-Abl PDGFR Autophagy	Cancer
Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits *c-Kit, Bcr-Abl, and PDGFR* (IC₅₀=100 nM) tyrosine kinases.

HY-112616

NAMPT inhibitor-linker 2	NAMPT Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 2 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC₅₀s of <7 pM and 40 pM, respectively.

HY-G0017

N-Desmethyl imatinib Norimatinib; Imatinib metabolite N-Desmethyl imatinib	Drug Metabolite	Others
N-Desmethyl imatinib (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-G0017A

N-Desmethyl imatinib mesylate Norimatinib mesylate; Imatinib metabolite N-Desmethyl imatinib mesylate	Drug Metabolite	Others
N-Desmethyl imatinib mesylate (Norimatinib mesylate) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-110071

APcK110	c-Kit	Cancer
APcK110 is a potent *Kit* inhibitor that can be used for the research of acute myeloid leukemia (AML). APcK110 induces AML cell apoptosis .

HY-112615

NAMPT inhibitor-linker 1	Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 1 is a agent-linker conjugates for ADC, composed of an NAMPT inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC₅₀s of <3 pM and 9 pM, respectively.

HY-16749A

Pexidartinib hydrochloride 85+ Cited Publications PLX-3397 hydrochloride	c-Fms c-Kit Apoptosis	Cancer
Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and *c-Kit* inhibitor, with IC₅₀s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity .

HY-10209

Masitinib 5 Publications Verification AB1010	c-Kit PDGFR Src FGFR FAK Apoptosis	Cancer
Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of *c-Kit* (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .

HY-10209A

Masitinib mesylate 5 Publications Verification AB-1010 mesylate	c-Kit PDGFR Src FGFR Apoptosis	Cancer
Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of *c-Kit* (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .

HY-101561

Avapritinib 5+ Cited Publications BLU-285	c-Kit PDGFR	Cancer
Avapritinib (BLU-285) is a highly potent, selective, and orally active *KIT* and PDGFRA activation loop mutant kinases inhibitor with IC₅₀s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2 .

HY-10501

SU14813 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and *KIT*.

HY-10501A

SU14813 maleate 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and *KIT*.

Cat. No.	Product Name	Type

HY-B1684

Mebrofenin SQ 26962	Indicators
Mebrofenin (SQ 26962) is a type of iminodiacetic acid (IDA). Mebrofenin is available as a ready to use the kit for radio-labeling with Tc-99m. Tc-99m Mebrofenin, a diagnostic agent, is used for hepatobiliary imaging. Tc-99m Mebrofenin is the radiopharmaceutical of choice for the evaluation of hepatic function .

Cat. No.	Product Name	Target	Research Area

HY-P99462

Barzolvolimab CDX 0159	c-Kit	Inflammation/Immunology
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .

HY-P990002

*Anti-Mouse CD117/c-Kit* Antibody (2B8)**	c-Kit	Cancer
Anti-Mouse CD117/c-Kit Antibody (2B8) is an IgG2b antibody inhibitor against mouse CD117. Derived from rat.

HY-P99488

Briquilimab JSP-191	Inhibitory Antibodies	Inflammation/Immunology Cancer
Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID) .

HY-P990851

*Anti-c-Kit/CD117 Antibody (SR-1)*	Inhibitory Antibodies	Others
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human *c-Kit/CD117. The recommend isotype control of Anti-c-Kit*/CD117 Antibody (SR-1): Mouse IgG2a kappa, Isotype Control (HY-P99978).

HY-P990020

Eglatoprutug	Inhibitory Antibodies c-Kit	Others
Eglatoprutug is an humanized immunoglobulin G1-kappa, anti-c-Kit monoclonal antibody .

HY-P990754

Opelkibart	c-Kit	Inflammation/Immunology
Opelkibart is an anti-KIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species:	Human (9) Rhesus Macaque (1) Mouse (5) Rat (4) Canine (1)
Tag:	His (11) Tag Free (3) GST (1) Fc (5) Flag (1)
Source:	HEK293 (13) Sf9 insect cells (1) E. coli (6)

Cat. No.	Compare	Product Name	Species	Source

HY-P72752

	*CD117/c-kit* Protein, Human (HEK293, His)** Mast/stem cell growth factor receptor KIT; SCFR; PBT; CD117; KIT	Human	HEK293
	CD117/c-kit is a tyrosine protein kinase receptor for KITLG/SCF that coordinates cell survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis. Upon KITLG/SCF binding, CD117 activates the pathway and phosphorylates PIK3R1, PLCG1, SH2B2/APS, and CBL. CD117/c-kit Protein, Human (HEK293, His) is the recombinant human-derived CD117/c-kit protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72879

	*CD117/c-Kit* Protein, Mouse (HEK293, Fc)** Mast/stem cell growth factor receptor KIT; SCFR; CD117; KIT; Sl	Mouse	HEK293
	CD117/c-Kit protein is a tyrosine protein kinase that acts as a cell surface receptor for KITLG/SCF and regulates cell survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, function, and melanogenesis . CD117/c-Kit Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD117/c-Kit protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P72880

	*CD117/c-Kit* Protein, Mouse (HEK293, His)** Mast/stem cell growth factor receptor KIT; SCFR; CD117; KIT; Sl	Mouse	HEK293
	CD117/c-Kit protein is a tyrosine protein kinase that acts as a cell surface receptor for KITLG/SCF and regulates cell survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, function, and melanogenesis .CD117/c-Kit Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD117/c-Kit protein, expressed by HEK293 , with C-10*His labeled tag.

HY-P74337

	*CD117/c-kit* Protein, Rat (HEK293, His)** Mast/stem cell growth factor receptor KIT; SCFR; CD117; KIT; Sl	Rat	HEK293
	CD117, also known as tyrosine-protein kinase KIT or mast/stem cell growth factor receptor (SCFR), is a cytokine receptor that is expressed on the surface of hematopoietic stem cells and other cell types. CD117 signaling pathway plays an important role in cell survival, proliferation and differentiation. CD117 is a proto-oncogene associated with tumor development. CD117/c-kit Protein, Rat (HEK293, His) is the recombinant rat-derived CD117/c-kit protein, expressed by HEK293 , with C-His labeled tag.

HY-P74336

	*CD117/c-kit* Protein, Rhesus Macaque (HEK293, Fc)** Mast/stem cell growth factor receptor KIT; SCFR; CD117; KIT; Sl	Rhesus Macaque	HEK293
	CD117, also known as tyrosine-protein kinase KIT or mast/stem cell growth factor receptor (SCFR), is a cytokine receptor that is expressed on the surface of hematopoietic stem cells and other cell types. CD117 signaling pathway plays an important role in cell survival, proliferation and differentiation. CD117 is a proto-oncogene associated with tumor development. CD117/c-kit Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived CD117/c-kit protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P78712

	*CD117/c-kit* Protein, Mouse (495a.a, HEK293, Fc)** CD117; SCFR; c-KIT; KIT	Mouse	HEK293
	CD117/c-Kit protein is a tyrosine protein kinase that acts as a cell surface receptor for KITLG/SCF and regulates cell survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, function, and melanogenesis .CD117/c-kit Protein, Mouse (495a.a, HEK293, Fc) is the recombinant mouse-derived CD117/c-kit protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P74338

	*CD117/c-kit* Protein, Rat (HEK293, Fc)** Mast/stem cell growth factor receptor KIT; SCFR; CD117; KIT; Sl	Rat	HEK293

HY-P74341

	*CD117/c-kit* Protein, Human (141a.a, His)** Mast/stem cell growth factor receptor KIT; SCFR; CD117; KIT; Sl	Human	E. coli
	CD117/c-kit is a tyrosine protein kinase receptor for KITLG/SCF that coordinates cell survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis. Upon KITLG/SCF binding, CD117 activates the pathway and phosphorylates PIK3R1, PLCG1, SH2B2/APS, and CBL. CD117/c-kit Protein, Human (141a.a, His) is the recombinant human-derived CD117/c-kit protein, expressed by E. coli , with N-His labeled tag.

HY-P73495

	*CD117/c-kit* Protein, Human (P10721-2, HEK293, His)** Mast/stem cell growth factor receptor KIT; SCFR; CD117; KIT; Sl	Human	HEK293
	CD117/c-kit is a tyrosine protein kinase receptor for KITLG/SCF that coordinates cell survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis. Upon KITLG/SCF binding, CD117 activates the pathway and phosphorylates PIK3R1, PLCG1, SH2B2/APS, and CBL. CD117/c-kit Protein, Human (P10721-2, HEK293, His) is the recombinant human-derived CD117/c-kit protein, expressed by HEK293 , with C-His labeled tag. The total length of CD117/c-kit Protein, Human (P10721-2, HEK293, His) is 491 a.a., with molecular weight of 75-85 kDa.

HY-P74339

	*CD117/c-kit* Protein, Human (P10721-2, HEK293, Fc)** Mast/stem cell growth factor receptor KIT; SCFR; CD117; KIT; Sl	Human	HEK293
	CD117/c-kit is a tyrosine protein kinase receptor for KITLG/SCF that coordinates cell survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis. Upon KITLG/SCF binding, CD117 activates the pathway and phosphorylates PIK3R1, PLCG1, SH2B2/APS, and CBL. CD117/c-kit Protein, Human (P10721-2, HEK293, Fc) is the recombinant human-derived CD117/c-kit protein, expressed by HEK293 , with C-hFc labeled tag. The total length of CD117/c-kit Protein, Human (P10721-2, HEK293, Fc) is 491 a.a., with molecular weight of 93-115 kDa.

HY-P702691

	*CD117/c-kit* Protein, Human (P10721-1, sf9)** KIT; v-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; PBT, piebald trait; mast/stem cell growth factor receptor KIT; C KIT; CD117; SCFR; p145 c-KIT; proto-oncogene c-KIT; piebald trait protein; soluble KIT variant 1; tyrosine-protein kinase KIT; proto-oncogene tyrosine-protein kinase KIT; v-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene-like protein; PBT; C-KIT	Human	Sf9 insect cells
	CD117/c-kit is a tyrosine protein kinase receptor for KITLG/SCF that coordinates cell survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis. Upon KITLG/SCF binding, CD117 activates the pathway and phosphorylates PIK3R1, PLCG1, SH2B2/APS, and CBL. CD117/c-kit Protein, Human (P10721-1, sf9) is the recombinant human-derived CD117/c-kit, expressed by Sf9 insect cells , with GST, Flag labeled tag. The total length of CD117/c-kit Protein, Human (P10721-1, sf9) is 433 a.a.,

HY-P72480

	SCF Protein, Rat (His) KIT ligand; MGF; SCF; c-KIT ligand; sKITLG; KITlg	Rat	E. coli
	Stem cell factor (SCF), as a key ligand of KIT, regulates cell survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis. Binding to KIT activates signaling pathways involving phosphorylation events, key kinases (AKT1, RAS, RAF1, MAPK1/ERK2, MAPK3/ERK1), STAT family members, and PLCG1. SCF Protein, Rat (His) is the recombinant rat-derived SCF protein, expressed by E. coli , with C-6*His labeled tag.

HY-P70757G

	GMP SCF Protein, Human (HEK293, His) 1 Publications Verification KIT Ligand; MGF; SCF; c-KIT ligand; KITLG; sKITLG	Human	HEK293
	SCF proteins are ligands for the KIT receptor-type protein tyrosine kinase and regulate a variety of cellular processes, including survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis. Binding to KIT activates signaling pathways involving PIK3R1, AKT1, GRB2, RAS, RAF1, MAP kinase, STAT family members, and PLCG1, producing diacylglycerol and inositol 1,4,5-trisphosphate. GMP SCF Protein, Human (HEK293, His) is the recombinant human-derived SCF protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P79111

	SCF Protein, Canine KIT ligand; Mast cell growth factor; MGF; Stem Cell Factor; SCF; c-KIT ligand; KITLG	Canine	E. coli
	SCF protein critically promotes mast cell proliferation, enhancing both myeloid and lymphoid hematopoietic progenitor proliferation in bone marrow. Additionally, SCF facilitates cell-cell adhesion and synergizes with other cytokines, potentially interleukins. As a homodimer, SCF is connected non-covalently, contributing to hematopoietic processes and immune responses. SCF Protein, Canine is the recombinant canine-derived SCF protein, expressed by E. coli , with tag free. The total length of SCF Protein, Canine is 165 a.a., with molecular weight of ~19 kDa.

HY-P70781

	SCF Protein, Human 3 Publications Verification KIT Ligand; Mast Cell Growth Factor; MGF; Stem Cell Factor; SCF; c-KIT ligand; KITLG; MGF; SCF	Human	E. coli
	SCF, Human, as a recombinant protein, plays essential roles in gametogenesis, melanogenesis and hematopoiesis. SCF, Human also plays an important role in nervous system.

HY-P70757

	SCF Protein, Human (HEK293, His) KIT Ligand; Mast Cell Growth Factor; MGF; Stem Cell Factor; SCF; c-KIT ligand; KITLG; MGF; SCF	Human	HEK293
	SCF proteins are ligands for the KIT receptor-type protein tyrosine kinase and regulate a variety of cellular processes, including survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis. Binding to KIT activates signaling pathways involving PIK3R1, AKT1, GRB2, RAS, RAF1, MAP kinase, STAT family members, and PLCG1, producing diacylglycerol and inositol 1,4,5-trisphosphate. SCF Protein, Human (HEK293, His) is the recombinant human-derived SCF protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P700148AF

	Animal-Free SCF Protein, Human (His) KIT Ligand; Mast Cell Growth Factor; MGF; Stem Cell Factor; SCF; c-KIT ligand; KITLG; MGF; SCF	Human	E. coli
	SCF proteins are ligands for the KIT receptor-type protein tyrosine kinase and regulate a variety of cellular processes, including survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis. Binding to KIT activates signaling pathways involving PIK3R1, AKT1, GRB2, RAS, RAF1, MAP kinase, STAT family members, and PLCG1, producing diacylglycerol and inositol 1,4,5-trisphosphate. Animal-Free SCF Protein, Human (His) is the recombinant human-derived animal-FreeSCF protein, expressed by E. coli , with C-His labeled tag.

HY-P70555

	SCF Protein, Mouse (HEK293, His) 1 Publications Verification FPH2; KIT ligand; KITl; KITLG; KL-1; Mast cell growth factor; MGF; MGFSHEP7; SCF; SCFStem cell factor; SFc-KIT ligand; SLF; steel factor	Mouse	HEK293
	SCF proteins are ligands for the KIT receptor-type protein tyrosine kinase and are critical for multiple cellular processes, including survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis.Binding to KIT activates multiple signaling pathways involving PIK3R1, AKT1, GRB2, RAS, RAF1, MAP kinase, STAT family members and PLCG1, producing signaling molecules.SCF Protein, Mouse (HEK293, His) is the recombinant mouse-derived SCF protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P71130

	SCF Protein, Rat (HEK293, His) FPH2; KIT ligand; KITl; KITLG; KL-1; Mast cell growth factor; MGF; MGFSHEP7; SCF; SCFStem cell factor; SFc-KIT ligand; SLF; steel factor	Rat	HEK293
	Stem cell factor (SCF), as a key ligand of KIT, regulates cell survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis. Binding to KIT activates signaling pathways involving phosphorylation events, key kinases (AKT1, RAS, RAF1, MAPK1/ERK2, MAPK3/ERK1), STAT family members, and PLCG1. SCF Protein, Rat (HEK293, His) is the recombinant rat-derived SCF protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P70528

	SCF Protein, Mouse KIT ligand; Hematopoietic growth factor KL; Mast cell growth factor; MGF; Steel factor; Stem cell factor; SCF	Mouse	E. coli
	SCF proteins are ligands for the KIT receptor-type protein tyrosine kinase and are critical for multiple cellular processes, including survival, proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration, and melanogenesis.Binding to KIT activates multiple signaling pathways involving PIK3R1, AKT1, GRB2, RAS, RAF1, MAP kinase, STAT family members and PLCG1, producing signaling molecules.SCF Protein, Mouse is the recombinant mouse-derived SCF protein, expressed by E.coli , with tag free.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10331S

Regorafenib-d3
Regorafenib-d₃ is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].

HY-15463S

Imatinib-d8 1 Publications Verification
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

HY-15463S1

Imatinib-d4
Imatinib-d₄ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].

HY-10981S

Lenvatinib-d4
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

HY-132451S

(R,S)-4-Hydroxy Cyclophosphamide-d4 Preparation Kit
(R,S)-4-Hydroxy Cyclophosphamide-d₄ Preparation Kit is the deuterium labeled (R,S)-4-Hydroxy Cyclophosphamide Preparation Kit. (R,S)-4-Hydroxy Cyclophosphamide is an isomer of 4-Hydroxycyclophosphamide, the active metabolite of the cytotoxic alkylating agent Cyclophosphamide (HY-17420) .

HY-10873S

N-Desethyl Sunitinib-d5
N-Desethyl Sunitinib-d₅ is the deuterium labeled N-Desethyl Sunitinib. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively[1].

HY-10873S2

N-Desethyl Sunitinib-d5 hydrochloride
N-Desethyl Sunitinib-d5 (hydrochloride) is a deuterated labeled N-Desethyl Sunitinib . N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and *KIT* inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

HY-10981S1

Lenvatinib-d5
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

HY-13904S

Flumatinib-d3
Flumatinib-d₃ is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively[1].

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-G0017S1

N-Desmethyl imatinib-d4
N-Desmethyl imatinib-d₄ is the deuterium-labeled N-Desmethyl imatinib (HY-G0017). N-Desmethyl imatinib-d₄ (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR .

HY-13342AS

Apatinib-d8 free base

Apatinib-d₈ (free base) is the deuterium labeled Apatinib free base[1]. Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ[2][3][4].

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-10981S2

Lenvatinib-15N,d4
Lenvatinib- ¹⁵N,d₄ is ¹⁵N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, *KIT, and RET*, shows potent antitumor activities .

HY-10330S

Toceranib-d8
Toceranib-d₈ is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].

HY-10331S1

Regorafenib-13C,d3
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-10230S

Midostaurin-d5
Midostaurin-d₅ is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM[1].

HY-15463S2

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-I0678S1

Regorafénib N-oxyde (M2)-13C,d3
Regorafénib N-oxyde (M2)- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

HY-I0678S

Regorafénib N-oxyde-d3 (M2)
Regorafénib N-oxyde-d₃(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].

HY-10201S2

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80085

	*c-Kit* Antibody (YA502)**	WB, IHC-P	Human
	c-Kit Antibody (YA502) is a non-conjugated and Rabbit origined monoclonal antibody about 110 kDa, targeting to c-Kit. It can be used for WB,IHC-P assays with tag free, in the background of Human.

HY-P80619

	*c-Kit* Antibody** KIT; SCFR; Mast/stem cell growth factor receptor KIT; SCFR; Piebald trait protein; PBT; Proto-oncogene c-KIT; Tyrosine-protein kinase KIT; p145 c-KIT; v-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; CD antigen CD117	WB, IHC-P	Human
	c-Kit Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 110 kDa, targeting to c-Kit. It can be used for WB,IHC-P assays with tag free, in the background of Human.

HY-P81128

	SCF Antibody Stem Cell Factor; C KIT ligand; CKIT ligand; DKFZp686F2250; KIT ligand; KITl; KITLG; KL 1; KL1; Mast cell growth factor; MGF; SF; SHEP7; Steel factor; Stem cell factor precursor; SCF_HUMAN.	WB, IHC-P, ICC/IF, FC	Human
	SCF Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-SCF monoclonal antibody. SCF Antibody can be used for: WB, IHC-P, ICC/IF, FC expriments in human background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: